Amicus Therapeutics aims for potentially disruptive $92M IPO
Amicus Therapeutics, a Cranbury, N.J., developer of drugs to treat rare genetic diseases, said it plans to raise as much as $92 million in an IPO — money that would fund its pursuit of new drugs for rare genetic diseases, a strategy could be disruptive for both medicine and the biotechnology landscape.
According to its SEC filing, Amicus plans to offer up to 5.75 million shares at a price of $14 to $16. The company’s market… Continue Reading